“We acknowledge there are significant challenges involved in securing reimbursement for innovative medicines in Australia, and our focus in the near term is on enabling private access so patients are not left waiting without options," said Manny Simons, General Manager of Lilly Australia and New Zealand. …
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
The PBS stands alone as the only major health and disability program going backwards
October 13, 2026 - - Latest News -
GBMA's Nikki Lorenz returns from global generics talks with WHO and WTO
October 13, 2026 - - Latest News -
Australian children with cancer are missing out on trials adults can access
October 13, 2026 - - Latest News